Tarceva and Warm shock - a phase IV clinical study of FDA data

Summary:

Warm shock is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Alimta, and have Lung adenocarcinoma.

The phase IV clinical study analyzes which people have Warm shock when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Warm shock?

Warm shock (septic shock) is found to be associated with 2,321 drugs and 3,327 conditions by eHealthMe. Check the latest studies of Warm shock.

On Mar, 30, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 42 people (0.14%) have Warm shock.

Among these 42 people:

How long have people been on Tarceva when they have Warm shock? *

What is the gender of people who have Warm shock when taking Tarceva? *

female: 47.62 %
male: 52.38 %

What is the age of people who have Warm shock when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides Warm shock? *

Pneumonia: 12 people, 28.57%
Respiratory Acidosis (respiratory failure or ventilatory failure, causes the ph of blood and other bodily fluids to decrease): 8 people, 19.05%
Diarrhea: 6 people, 14.29%
Acute Kidney Failure: 5 people, 11.90%
Sepsis (a severe blood infection that can lead to organ failure and death): 4 people, 9.52%
Multi-Organ Failure (multisystem organ failure): 3 people, 7.14%
Haemorrhage (bleeding): 3 people, 7.14%
Hypotension (abnormally low blood pressure): 3 people, 7.14%
Malaise (a feeling of general discomfort or uneasiness): 3 people, 7.14%
Dehydration (dryness resulting from the removal of water): 3 people, 7.14%

What are the existing conditions these people have? *

Lung Adenocarcinoma (a form of non-small cell lung cancer): 7 people, 16.67%
Lung Neoplasm Malignant (cancer tumour of lung): 6 people, 14.29%
Tumor: 3 people, 7.14%
Adenocarcinoma (malignant tumour formed from glandular structures in epithelial tissue): 3 people, 7.14%
Pancreatic Carcinoma (pancreatic cancer): 2 people, 4.76%
Pain: 2 people, 4.76%
Malignant Pleural Effusion (a condition in which cancer causes an abnormal amount of fluid to collect between the thin layers of tissue lining of lung): 2 people, 4.76%
Atrial Fibrillation/flutter (atrial fibrillation and flutter are abnormal heart rhythms in which the atria, or upper chambers of the heart, are out of sync with the ventricles): 2 people, 4.76%
Lung Adenocarcinoma Stage Iv (the cancer has spread to other organs of the body, such as the other lung, brain, or liver): 2 people, 4.76%
Diabetes: 1 person, 2.38%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Warm shock?

- Check whether Warm shock is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Warm shock treatments and more:

Warm shock (51,128 reports)

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Warm shock:

Warm shock (2,321 drugs)

Browse all the conditions that are associated with Warm shock:

Warm shock (3,327 conditions)

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.